Cogent Biosciences, Inc.
COGT
Peringkat dalam Saham
#3228
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Harga Saham
$31.49
Terakhir disinkronkan: 2026-10-21
Kapitalisasi Pasar
$5.46B
Perubahan (1 hari)
0.81%
Perubahan (1 tahun)
112.08%
Negara
US
Perdagangan Cogent Biosciences, Inc. (COGT)
Kategori
Healthcare
Riwayat harga saham Cogent Biosciences, Inc. (COGT)
Harga penutupan tertinggi: $30.19 pada 2026-10-01
Harga penutupan terendah: $44.44 pada 2018-03-01
Harga penutupan terendah: $44.44 pada 2018-03-01
Riwayat harga saham Cogent Biosciences, Inc. dari 2018 hingga 2026
Performa harga saham tahunan
| Tahun | Performa |
|---|---|
| 2026 (TTM) | -10.69% |
| 2025 | 364.44% |
| 2024 | 37.29% |
| 2023 | -46.89% |
| 2022 | 39.37% |
| 2021 | -29.74% |
| 2020 | 349.09% |
| 2019 | -87.13% |
| 2018 | 0.00% |
Harga saham perusahaan atau pesaing serupa
| Perusahaan | Harga saham | Perubahan 1th% | Negara |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $755.78 | 7.42% |
CH
|
